

SCIENTIFIC REPORTS



OPEN

Luteolin inhibits GABA_A receptors in HEK cells and brain slices

Mei-Lin Shen¹, Chen-Hung Wang², Rita Yu-Tzu Chen³, Ning Zhou^{2,3}, Shung-Te Kao¹ & Dong Chuan Wu^{2,3}

Received: 19 April 2016

Accepted: 24 May 2016

Published: 13 June 2016

Modulation of the A type γ -aminobutyric acid receptors (GABA_AR) is one of the major drug targets for neurological and psychological diseases. The natural flavonoid compound luteolin (2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-chromenone) has been reported to have antidepressant, antinociceptive, and anxiolytic-like effects, which possibly involve the mechanisms of modulating GABA signaling. However, as yet detailed studies of the pharmacological effects of luteolin are still lacking, we investigated the effects of luteolin on recombinant and endogenous GABA_AR-mediated current responses by electrophysiological approaches. Our results showed that luteolin inhibited GABA-mediated currents and slowed the activation kinetics of recombinant α 1 β 2, α 1 β 2 γ 2, α 5 β 2, and α 5 β 2 γ 2 receptors with different degrees of potency and efficacy. The modulatory effect of luteolin was likely dependent on the subunit composition of the receptor complex: the $\alpha\beta$ receptors were more sensitive than the $\alpha\beta\gamma$ receptors. In hippocampal pyramidal neurons, luteolin significantly reduced the amplitude and slowed the rise time of miniature inhibitory postsynaptic currents (mIPSCs). However, GABA_AR-mediated tonic currents were not significantly influenced by luteolin. These data suggested that luteolin has negative modulatory effects on both recombinant and endogenous GABA_ARs and inhibits phasic rather than tonic inhibition in hippocampus.

Luteolin (PubChem CID: 5280445) is a naturally occurring flavone with four additional hydroxyl groups at C3', C4', C5 and C7 on the flavone backbone of 2-phenylchromen-4-one (2-phenyl-1-benzopyran-4-one)¹. Luteolin is found in many vegetables and medical herbs, such as *Perilla frutescens*^{2,3}. The pharmacological effects of luteolin have been widely reported, such as antioxidant, anticarcinogenic, and anti-inflammatory activities^{3,4}. Interestingly, recent studies have indicated that luteolin might have psychopharmacological effects in the central nervous system (CNS) at least partially through activation of GABA_ARs⁵⁻¹⁰. However, detailed studies that examine the pharmacological effects of luteolin on GABA_AR functions are still lacking.

GABA_ARs are the major inhibitory receptors in the CNS. At least 19 subunits of GABA_ARs exist in the human nervous system, including α 1-6, β 1-3, γ 1-3, δ , θ , π , ϵ and ρ 1-3¹¹. The expression of GABA_AR subunits is not limited to the nervous system but is also widely found in peripheral non-neuronal organs, including the lung, pancreas, gut etc. In the peripheral systems such as the lung tissue, endogenous GABA_ARs could either exist as the $\alpha\beta$ isoform or incorporate a γ -like subunit^{12,13}. These peripheral GABA_ARs are involved in various physiological and pathological conditions, including modulation of glucagon release, mucus overproduction, and prevention of cell death in pancreas and liver¹³⁻¹⁷. In the adult CNS, the major isoforms of GABA_ARs are composed of α , β , and γ subunits^{12,18}. Varied compositions of GABA_ARs are differently distributed in synaptic and extrasynaptic regions of the inhibitory synapses to control balance between neuronal excitation and inhibition for normal brain functions. The high diversity of subunit compositions indicates that the GABA_AR subtypes located at different brain regions and different subsynaptic loci are engaged in distinct functions¹⁹. For example, in the hippocampus, the α 1 β 2 γ 2 GABA_ARs mediate the phasic inhibitory transmission at synapse, whereas the α 5 β 2 γ 2 GABA_ARs are located at extrasynaptic sites to mediate tonic inhibition in response to ambient release of GABA¹². Previous studies showed that knockout α 5 subunit of GABA_ARs or selective inhibition of α 5 β 2 γ 2 function improved learning and memory abilities^{20,21}, while enhancement of synaptic GABA_AR function has always been an important target of treating epilepsy, anxiety, and other psychiatric/neurological diseases¹².

¹Graduate Institute of Chinese Medicine, China Medical University, Taichung, Taiwan. ²Graduate Institute of Clinical Medical Science, China Medical University, Taichung, Taiwan. ³Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan. Correspondence and requests for materials should be addressed to N.Z. (email: ningzhou@mail.cmu.edu.tw) or S.-T.K. (email: stkao@mail.cmu.edu.tw) or D.C.W. (email: dongchuanwu@mail.cmu.edu.tw)




Figure 1. Inhibition of GABA-activated currents by luteolin in the recombinant GABA_ARs. Recombinant GABAARs composed by $\alpha 1\beta 2$ (A), $\alpha 1\beta 2\gamma 2$ (B), $\alpha 5\beta 2$ (C), and $\alpha 5\beta 2\gamma 2$ (D) were first activated by GABA in the absence of luteolin (circles). Dose-response relationships were calculated from the value of peak whole-cell current amplitudes induced by varying GABA concentrations normalized to the value of I_{max} that were activated by maximum GABA concentration. In the presence of 50 μM of luteolin (square), the amplitudes of GABA-activated currents were also normalized to the value of I_{max} of the same cell. All data points and bars represent mean values \pm s.e.m. More detailed data for the dose-response curves of GABAARs are presented in Table 1.

Despite accumulating studies suggesting a modulatory effect of luteolin on GABA_ARs in the CNS^{7,9}, the pharmacological characterization of luteolin still remains unclear. For instance, studies have shown that luteolin has antidepressant and analgesic effects that are considered to be mediated by enhancing GABA_AR functions^{6,8}; however, luteolin did not exhibit any pro- or anti-convulsant effects in various animal models of epilepsy²². Furthermore, luteolin has been reported to enhance learning and memory in a neurodegenerative model¹⁰. Children with autism spectrum disorders showed improvement in adaptive functioning after receiving dietary supplement of flavonoids including luteolin (100 mg/10 kg weight daily)²³, which produced an estimated concentration of $\sim 8.7 \mu\text{mol/L}$ in plasma according to a study on the relationship between oral intake and plasma concentration of luteolin²⁴. Hence, these previous studies have led us to hypothesize that luteolin might have varied effects on different subtypes of GABA_ARs to achieve the complex neuropharmacological influences. To elucidate the pharmacological mechanisms underlying these study results, we investigated the sensitivities of $\alpha 1$ - and $\alpha 5$ -containing GABA_ARs to different doses of luteolin in HEK cells. Furthermore, the effect of luteolin on $\alpha 1$ - and $\alpha 5$ -containing GABA_AR-mediated phasic and tonic inhibition in hippocampal slices was also studied.

Results

Effects of luteolin on dose-response relationships of GABA_ARs in HEK cells. Inclusion of α and β subunits is required to create functional GABA_AR pentamers and the $\alpha\beta$ receptors are already sufficient for insertion into the plasma membrane. Despite low levels of expression, the $\alpha\beta$ receptors naturally exist in the CNS and in peripheral systems^{13,25}. The $\alpha\beta$ receptors are also useful for molecular pharmacology studies using recombinant expression systems like HEK cells. The $\alpha\beta\gamma$ receptors are the most abundant form of GABA_ARs in the CNS and are sensitive to benzodiazepine potentiation. Among the $\alpha\beta\gamma$ compositions, the $\alpha 1\beta 2\gamma 2$ receptors are the most predominant form and are ubiquitously distributed in inhibitory synapses to mediate phasic inhibition, whereas $\alpha 5\beta 2\gamma 2$ receptors are predominantly located at the extrasynaptic region to mediate the tonic inhibition in hippocampus. In the present study, we selected recombinant $\alpha 1\beta 2$, $\alpha 1\beta 2\gamma 2$, $\alpha 5\beta 2$, and $\alpha 5\beta 2\gamma 2$ GABA_ARs to characterize the pharmacological effects of luteolin.

Whole-cell recordings were performed in HEK293T cells expressed with $\alpha 1\beta 2$, $\alpha 1\beta 2\gamma 2$, $\alpha 5\beta 2$, or $\alpha 5\beta 2\gamma 2$ subunits of GABA_ARs. Fast-perfusion of GABA (0.1–500 μM) produced inward current responses at a holding membrane potential of -60 mV . Recombinant expression of GABA_ARs resulted in dose-response curves with EC₅₀ values within a range of 2 to 4 μM (Fig. 1, Table 1). Extracellular application of luteolin (50 μM) inhibited current responses induced by the agonist from medium to saturating doses (1–500 μM GABA) in all tested forms of GABA_ARs. Although the maximum currents (I_{max}) of GABA_ARs were substantially reduced by luteolin, the EC₅₀ was relatively less affected (with 0.8-, 1.7-, 1.6-, and 2.1-fold changes by 50 μM luteolin in $\alpha 1\beta 2$, $\alpha 1\beta 2\gamma 2$, $\alpha 5\beta 2$, and $\alpha 5\beta 2\gamma 2$ receptors, respectively, Table 1). These results indicate that luteolin is likely a non-competitive antagonist of GABA_ARs.

| Subunit Composition | Treatment | EC ₅₀ (μM) | Hill Coefficient | I _{max} Normalized to Control (%) | n |
|---------------------|-----------|-----------------------|------------------|--|----|
| α1β2 | Control | 2.72 ± 0.35 | 1.31 | 100 | 14 |
| | Luteolin | 2.00 ± 0.75 | 1.10 | 42.4 ± 3.2 | 14 |
| α1β2γ2 | Control | 4.18 ± 0.60 | 1.55 | 100 | 12 |
| | Luteolin | 6.62 ± 2.11 | 0.97 | 66.5 ± 6.8 | 12 |
| α5β2 | Control | 2.71 ± 0.42 | 1.19 | 100 | 9 |
| | Luteolin | 4.34 ± 2.52 | 0.72 | 53.0 ± 5.5 | 9 |
| α5β2γ2 | Control | 2.48 ± 0.51 | 1.37 | 100 | 10 |
| | Luteolin | 5.10 ± 0.98 | 0.39 | 82.4 ± 5.6 | 10 |

Table 1. Data of dose-response relationship for recombinant GABA_ARs before and after luteolin (50 μM) treatment. Data from whole-cell recordings made from GABA_ARs expressed in HEK293T cells. I_{max}, maximum currents. Data represent the mean ± S.E.M.




Figure 2. Inhibition curves of luteolin in the recombinant GABA_ARs. GABA currents were activated by 3 μM of GABA in α1β2 (n = 8) (A) and α1β2γ2 (n = 10) (B) receptors, and by 2 μM of GABA in α5β2 (n = 10) (C) and α5β2γ2 receptors (n = 10) (D). Inhibition curves were calculated by normalizing values of the relative currents obtained following application of varying concentrations of luteolin to the values obtained in the absence of luteolin. All data points and bars represent mean values ± s.e.m.

Potency and efficacy of luteolin on different forms of GABA_ARs. We next examined the potency and efficacy of luteolin on the four forms of GABA_ARs by testing the dose-response relationship of luteolin-mediated inhibition. 0.1–100 μM of luteolin was included in the perfusion solution and was applied onto the same cell in sequence. By using medium doses of GABA to induce current responses, luteolin strongly inhibited GABA currents at concentrations >= 10 μM (Fig. 2), which exhibited a similar pattern to the effects of other flavonoids like apigenin and quercetin on GABA_ARs^{26,27}. By comparing the IC₅₀ of luteolin on the four types of GABA_ARs, we found that luteolin inhibited GABA currents with similar potency, with the lowest IC₅₀ in α1β2 (10.8 ± 4.46 μM). In the other forms, the IC₅₀ values of luteolin are 51.4 ± 242.8 μM in α1β2γ2, 25.4 ± 9.0 μM in α5β2, and 27.5 ± 13.8 μM in α5β2γ2. Moreover, the inhibitory efficacy of luteolin was assessed by the extent of reduction in I_{max}. Our results showed that luteolin had better efficacy on α1β2 and α5β2 receptors (Table 1). Inclusion of the γ2 subunit decreased the efficacy of luteolin, suggesting that the γ2 subunit is not required for forming luteolin binding site for its inhibition.

We also compared the inhibitory efficacy of luteolin on current responses mediated by medium or high doses of GABA. In the α1β2 and α5β2 receptors, both medium- and high-dose GABA-mediated currents were significantly inhibited by 50 μM of luteolin (Fig. 3A,C). In the α1β2γ2 receptors, however, luteolin had an inhibitory effect on 500 μM but not 3 μM GABA-induced currents (Fig. 3B). In the α5β2γ2 receptors, luteolin showed a better efficacy on 2 μM compared with 500 μM GABA-mediated currents (Fig. 3D). Taken together, these data




Figure 3. Inhibition effect of luteolin on medium versus high dose of GABA-activated current responses in recombinant $GABA_A$ Rs. Representative current traces showed medium or high doses of GABA-activated current responses in $\alpha 1\beta 2$ (A), $\alpha 1\beta 2\gamma 2$ (C), $\alpha 5\beta 2$ (E), and $\alpha 5\beta 2\gamma 2$ receptors (G) before and after $50\ \mu\text{M}$ of luteolin. The quantitative results of luteolin inhibition were calculated from the value of GABA currents in the presence of luteolin normalized to the value before luteolin in $\alpha 1\beta 2$ ($n = 9$) (B), $\alpha 1\beta 2\gamma 2$ ($n = 9$) (D), $\alpha 5\beta 2$ ($n = 10$) (F), and $\alpha 5\beta 2\gamma 2$ receptors ($n = 10$) (H). All data points and bars represent mean values \pm s.e.m. * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; n.s., no significance using student's t-test.

showed that luteolin exhibited varied degrees of potency and efficacy to reduce current responses of different forms of $GABA_A$ Rs.

Luteolin affected activation kinetics of $GABA_A$ Rs. Activation kinetics of GABA currents can influence the time course of the neurotransmitter-evoked responses at the synapses²⁸. In the present experiments, currents were elicited by fast perfusion of GABA at concentrations close to EC_{50} , and the activation kinetics were characterized by the 10–90% activation time of the current after fast perfusion of GABA. Luteolin at high concentrations




Figure 4. Luteolin slowed the activation of recombinant GABA_ARs. Representative current traces (superimposed and scaled) illustrating the effect of 0.1 and 100 μM of luteolin on current activation of $\alpha 1\beta 2$ (A), $\alpha 1\beta 2\gamma 2$ (C), $\alpha 5\beta 2$ (E), and $\alpha 5\beta 2\gamma 2$ receptors (G). The quantitative results summarized the 10–90% activation time calculated for control currents or after 0.1 and 100 μM of luteolin in $\alpha 1\beta 2$ (n = 15) (B), $\alpha 1\beta 2\gamma 2$ (n = 10) (D), $\alpha 5\beta 2$ (n = 10) (F), and $\alpha 5\beta 2\gamma 2$ receptors (n = 10). All data points and bars represent mean values \pm s.e.m. **P < 0.01 compared with control using one-way ANOVA.

(100 μM) slowed the activation time in all tested forms of GABA_ARs (Fig. 4). In the presence of 100 μM luteolin, the activation time of $\alpha 1\beta 2$, $\alpha 1\beta 2\gamma 2$, $\alpha 5\beta 2$, and $\alpha 5\beta 2\gamma 2$ GABA_ARs after luteolin treatment was increased by 3.5-, 2.4-, 5.8-, and 4.1-fold, respectively. Luteolin concentration lower than 10 μM had no significant effects on




Figure 5. The effect of luteolin on mIPSCs in hippocampal slices. (A) Representative traces showed mIPSCs recorded before (top trace) or after 100 μM of luteolin treatment (middle trace) in a hippocampal CA1 pyramidal neuron. 10 μM of bicuculline was applied at the end of the experiment to eliminate mIPSCs (bottom trace). (B) Cumulative probability plots of mIPSC amplitudes (left) and inter-event intervals (right) from the recorded neuron shown in (A). (C–E) Summary of changes in mean mIPSC amplitudes (C), mean frequencies (D), and mean rise time (E) after 0.1 ($n=7$) or 100 μM ($n=9$) luteolin treatments. All data points and bars represent mean values \pm s.e.m. * $P < 0.05$, ** $P < 0.01$ compared with control using one-way ANOVA.

GABA_AR activation time. Here we selected 0.1 and 100 μM as the representative doses of luteolin to show their effects on the activation kinetics of GABA currents. Our data suggested that higher doses of luteolin prolonged activation time of GABA_ARs (Fig. 4).

Effects of luteolin on phasic currents mediated by GABA_ARs in hippocampal slices. The hippocampus is the critical locus for learning and memory. The $\alpha 1\beta 2\gamma 2$ GABA_ARs are located at the postsynaptic site of inhibitory synapses and predominantly mediate the fast inhibitory synaptic currents in hippocampus. To further investigate the pharmacological modulation of luteolin on endogenous $\alpha 1\beta 2\gamma 2$ GABA_ARs under physiological conditions, we tested the effect of luteolin on phasic inhibition in hippocampal slices. The GABA_AR-mediated mIPSCs were pharmacologically isolated by inclusion of the sodium channel blocker TTX (0.5 μM) and the AMPA/kainate receptor blocker CNQX (20 μM). At the end of each experiment, the GABA_AR antagonist bicuculline (10 μM) was applied to confirm that the mIPSCs were abolished (Fig. 5A). Here we selected two representative doses (0.1 and 100 μM) to test the effect of luteolin. We showed that 100 μM luteolin significantly decreased the amplitude ($87.7 \pm 3.4\%$ normalized to baseline) but not the frequency ($103.6 \pm 6.2\%$) of mIPSCs (Fig. 5A–D). The rise time of mIPSCs was also significantly slower after high dose of luteolin treatments ($108.6 \pm 2.0\%$)




Figure 6. The effect of luteolin on tonic inhibitory currents in hippocampal slices. (A) The representative recording showed the tonic currents before and after 100 μM of luteolin treatments in a CA1 pyramidal neuron. The tonic current was revealed by 10 μM bicuculline at the end of the experiment. (B,C) Whisker plots (boxes, 25–75%, whiskers, Min–Max; lines, median; +, mean) showed that 0.1 μM (n = 6) (B) or 100 μM of luteolin (n = 10) (C) had no significant effects on tonic inhibition by using student's t-test.

(Fig. 5E). In contrast, 0.1 μM luteolin did not show any significance in changing the frequency ($93.7 \pm 3.1\%$), amplitude ($98.9 \pm 0.9\%$), or the rise time ($102.7 \pm 2.7\%$) of mIPSCs (Fig. 5C–E). Together, these data indicated that luteolin exerts negative modulation on phasic inhibitory responses by reducing the amplitude and slowing down the activation time of synaptic currents.

Effects of luteolin on tonic currents mediated by GABA_ARs in hippocampal slices. The $\alpha 5\beta 2\gamma 2$ GABA_ARs are located at the extrasynaptic site and mediate tonic inhibition in hippocampus. Our data have shown that, in the recombinant $\alpha 5\beta 2\gamma 2$ GABA_ARs, luteolin inhibited medium to high doses GABA-mediated responses. Considering that tonic inhibitory currents in the CNS are ascribed to the low concentration of ambient GABA in the extracellular space (from 0.2 to 2.5 μM)²⁹, it still remained to be determined whether luteolin has any modulatory effect on the low-dose GABA-mediated responses in slices. In our experiments, tonic currents were defined as the shift of holding currents after application bicuculline (10 μM). In some experiments, we also included a low dose of GABA in the bath solution (0.5 μM) to unify the ambient GABA concentration. Treatments with 0.1 or 100 μM luteolin did not significantly affect the amplitudes of tonic currents ($P > 0.05$ for both 0.1 and 100 μM groups) (Fig. 6). These results suggested that luteolin did not influence extrasynaptic GABA_AR-mediated tonic inhibitory currents.

Discussion

The pharmacological effect of luteolin on recombinant and endogenous GABA_ARs. Luteolin has been widely studied for its pharmacological effects, including anti-inflammatory, anti-oxidant, and anticarcinogenic activities. Recent studies have suggested that luteolin might enhance the function of GABA_ARs, thereby producing antihyperalgesic, anxiolytic, and antidepressant-like effects in the CNS^{5,6,8}. However, it still remains unclear whether luteolin takes these effects by directly targeting on GABA_ARs. In the brain, modulation of distinct subunit compositions of GABA_ARs is associated with different neurological and behavioral outcomes. Enhancements of $\alpha 1\beta 2\gamma 2$ GABA_ARs that mainly mediate fast synaptic inhibition generally produce sedative effects, while inhibition of $\alpha 5\beta 2\gamma 2$ GABA_ARs by either pharmacological or transgenic approaches can promote learning and memory. In the present study, we showed that low concentration of luteolin (0.1 μM) did not affect either GABA_AR-mediated phasic or tonic currents. In contrast, high concentration of luteolin (100 μM) reduced the amplitude of mIPSCs and prolonged the activation time course, but had no effect on mIPSC frequency. This indicated that the effect of luteolin was likely due to postsynaptic rather than presynaptic modulation. The inhibition of mIPSCs by luteolin was consistent with the observation from HEK cells: high concentration of luteolin suppressed the amplitude and prolonged the activation kinetics in recombinant GABA_ARs including the $\alpha 1\beta 2\gamma 2$ form. Although we have shown that luteolin reduced current responses that were induced by high dose but not

medium dose of GABA in recombinant $\alpha 1\beta 2\gamma 2$ receptors (Fig. 3D), it was still in line with the results from slices since vesicular release of GABA at synapses normally reaches a very high concentration³⁰. Furthermore, our results are consistent with previous studies that luteolin did not affect the threshold of seizure induction by picrocarpine or electrical stimuli in animal models²², suggesting that luteolin cannot produce obvious sedative effect through enhancement of the function of $\alpha 1\beta 2\gamma 2$ GABA_ARs.

The tonic inhibition in hippocampus was unaffected by luteolin even at concentrations as high as 100 μ M. However, the $\alpha 5\beta 2\gamma 2$ GABA_AR-mediated responses in HEK cells were significantly reduced. This could be ascribed to the low concentration of ambient GABA in the extracellular space in hippocampal slices, since luteolin showed very weak efficacy to modulate low dose of GABA-mediated responses (at [GABA] < 1 μ M) (Fig. 1D). Therefore, our findings indicated that luteolin is a negative modulator for GABA_ARs and did not have any potentiating effect on phasic or tonic inhibition in hippocampus.

Previous studies of luteolin mostly focused on the *in vivo* effects. One of the major differences between the *in vivo* and *in vitro* environments is the temperature. In our study, we performed *in vitro* electrophysiological experiments in room temperature (23–25 °C), which was lower than the body temperature (37 °C). Notably, some allosteric modulators, such as zolpidem, can modulate GABA_ARs in a temperature-dependent manner³¹. The affinity of zolpidem to GABA_ARs increased along with the increasing temperature from 16, 26 to 36 °C³¹. Previous studies showed that luteolin was stable at 37 °C in culture medium for 24 hours³². We thereby predict that luteolin might consistently take effects and show increased inhibition on GABA_ARs *in vivo*. Moreover, our data revealed that luteolin showed stronger inhibitory effects on recombinant GABA_ARs in HEK cells than in the endogenous GABA_ARs in brain slices. It was possibly due to the lack of synaptic scaffolding proteins in HEK cells and this might affect luteolin-mediated inhibition on GABA_ARs as suggested by previous studies³³.

Luteolin likely targets at non-benzodiazepine binding sites of GABA_ARs. Benzodiazepines are one of the most potent positive modulators of γ -containing GABA_ARs and the binding site is located at the $\alpha(+)/\gamma(-)$ interface. Previous studies have indicated the structural similarity between flavones and benzodiazepine ligands³⁴. Among different types of flavones, the presence of electronegative groups at the C6 and C3' position are critical determinants for high affinity to the benzodiazepine-binding site³⁵. For instance, hispidulin (4',5,7-trihydroxy-6-methoxyflavone) bearing a methoxyl group at C6 is a potent benzodiazepine site ligand and potentiates GABA_AR-mediated responses in $\alpha 1\beta 2\gamma 2$ form but not in $\alpha 1\beta 2$ form receptors³⁶. The structure of luteolin (5,7,3',4'-Tetrahydroxyflavone) is similar to apigenin (5,7,4'-Trihydroxyflavone) and quercetin (3,5,7,3',4'-Pentahydroxyflavone), all of which lack electronegative moieties at C6. Previous studies have demonstrated that luteolin and quercetin have weak affinities for the benzodiazepine site, with K_i values over 100 μ M for the [3H] flunitrazepam binding competition³⁵. Apigenin exhibited a higher affinity for central benzodiazepine receptors (with a K_i of 4 μ M to compete [3H] flunitrazepam binding)³⁷ and exerted anxiolytic and antidepressant effects in *in vivo* animal models. However, whether a direct involvement of GABA_ARs in the CNS is responsible of the effects of apigenin remains questionable. Electrophysiological studies showed that apigenin and quercetin similarly inhibited GABA-induced currents, while the inhibition of apigenin on $\alpha 1\beta 2\gamma 2$ GABA_AR-mediated responses were not prevented by the benzodiazepine site antagonist flumazenil²⁶. These studies indicated that, different from the traditional anxiolytic chemical benzodiazepine, the CNS effects of apigenin and quercetin are not likely due to their direct interaction and potentiation of GABA_ARs. In the present study, we found that luteolin negatively modulated GABA_ARs that lacked γ subunits. In agreement with previous studies using the [3H] flunitrazepam binding assay, our results indicated that luteolin inhibited GABA_ARs through non-benzodiazepine site of GABA_ARs. Such a modulatory effect of luteolin is in resemblance of that of apigenin and quercetin. We did not observe apparent potentiation effects of luteolin on either $\alpha 1$ - or $\alpha 5$ -containing GABA_ARs that were reported for hispidulin, likely due to the lack of a hydroxyl group at the C6 position of flavone⁹. Therefore, although we did not exclude the possible interaction between benzodiazepine sites and luteolin's metabolites, the direct effect of luteolin on GABA_ARs did not involve binding to central benzodiazepine receptors. In other words, the CNS effects of luteolin are likely obtained through other pharmacological mechanisms, possibly similar to those of apigenin and quercetin due to their structural similarity.

Different modulation on $\alpha\beta$ and $\alpha\beta\gamma$ forms of GABA_ARs indicated possible luteolin-binding sites.

During the development of benzodiazepine ligands, researchers have discovered new allosteric modulation sites on GABA_ARs. Ramerstorfer *et al.* have revealed a new ligand-binding site at the $\alpha(+)/\beta(-)$ interface that was independent from the benzodiazepine site at the $\alpha(+)/\gamma(-)$ interface³⁸. This new binding site was discovered by screening of benzodiazepine site ligand and was determined by CGS 9895 that could potentiate GABA_ARs in a flumazenil insensitive manner regardless of the incorporation of γ subunits, indicating that CGS 9895 targets on non-BZ-binding sites of GABA_ARs³⁸. Interestingly, CGS 9896, which is a structural analog of CGS 9895, exhibited a similar manner to 6-Methylflavone in a pharmacophore model of benzodiazepine site binding³⁴. Given that the inhibition by luteolin, apigenin, and quercetin is independent from γ incorporation and is insensitive to flumazenil, it is reasonable to speculate the possibility that these flavones might interact with the newly identified CGS 9895-binding site at the $\alpha(+)/\beta(-)$ interface. Our results showed that luteolin had more potent effects on the $\alpha\beta$ compared with the $\alpha\beta\gamma$ receptors, agreeing with the fact that the $\alpha\beta$ receptors embrace two $\alpha(+)/\beta(-)$ interfaces while the $\alpha\beta\gamma$ form only contains one $\alpha(+)/\beta(-)$ interface. However, the limited information about the exact molecular location of CGS 9895-binding site precludes further investigation of this hypothesis. In addition, we cannot rule out the possibility that luteolin targets on other modulation sites like the neurosteroid-binding site, which is located at the transmembrane domains of GABA_ARs.

Methods

cDNA constructs and transfection. Rat GABA_AR α 1, α 5, β 2, and γ 2 subunits were subcloned into the pCDNA3.1 expression vector. HEK293T cells (6×10^5) were transfected with purified plasmids encoding GABA_ARs (total plasmid amount 2–2.5 μ g) by electroporation (NEPA21, NEPA GENE). A small amount (0.2 μ g) of pcDNA3-GFP was co-transfected along with GABA_ARs to act as a transfection marker and facilitate the visualization of transfected cells during electrophysiological experiments. After transfection, cells were re-plated on poly-(D-lysine)-coated glass coverslips and were grown in DMEM in 24-well plates for 16–24 h before patch-clamp recordings.

Slice preparation. Hippocampal slices were prepared from 12–21-day-old ICR mice. Treatments of animals were evaluated and approved by the Institutional Animal Care and Use Committee of China Medical University according to Care of the animals and surgical procedures of China Medical University Protocols. Mice were anaesthetized with Urethane and decapitated. Brains were removed into ice-cold slicing solution containing (in mM): 230 sucrose, 26 NaHCO₃, 10 D-glucose, 2.5 KCl, 1.25 NaH₂PO₄, 0.5 CaCl₂, and 10 MgSO₄. 350 μ m-thick transverse hemi-sections from hippocampus were sliced (Leica vibratome) in the slicing solution. Then the slices were transferred to a storage chamber or the recording chamber with fresh artificial cerebrospinal fluid (ACSF) containing the following (in mM): 128 NaCl, 2.5 KCl, 2.0 MgCl₂, 2.0 CaCl₂, 1.25 NaH₂PO₄, 26 NaHCO₃, and 10 D-glucose, and were incubated at room temperature for >1 h before recording. All solutions were saturated with 95% O₂/5% CO₂.

Electrophysiology. For recording HEK cells, whole-cell patch clamp recordings were performed under voltage-clamp mode using the AXOPATCH 200B amplifier (Molecular Devices, USA). Whole-cell currents were recorded with a holding potential of –60 mV and signals were acquired via a Digidata 1440A analog-to-digital interface and were low-pass filtered at 2 kHz and digitized at 10 kHz. Patch electrodes (3–7 M Ω) were pulled from 1.5 mm outer diameter thin-walled glass capillaries in three stages on a Flaming–Brown micropipette puller and were filled with intracellular solutions (ICS), which contained (in mM) 140 CsCl, 10 HEPES, 4 Mg-ATP and 0.5 BAPTA (pH 7.20, osmolarity, 290–295 mOsm). The coverslips were continuously superfused with the extracellular solution containing (in mM): 140 NaCl, 5.4 KCl, 10 HEPES, 1.0 MgCl₂, 1.3 CaCl₂ and 20 glucose (pH 7.4, 305–315 mOsm). To evoke GABA currents, we used fast perfusion of GABA with a computer-controlled multibarrel fast perfusion system (Warner Instruments, CT, USA). For recording hippocampal neurons, slices were perfused with ACSF. Hippocampal CA1 pyramidal neurons were recorded with whole-cell patch clamp with a holding potential of –60 mV under voltage-clamp model using the MultiClamp 700B amplifier (Molecular Devices, USA). Recording pipettes (3–7 M Ω) were filled with the ICS that was mentioned above. For testing the effects of luteolin, slices were pretreated with luteolin for 5–10 min. For recording miniature inhibitory postsynaptic currents (IPSCs), all bath solutions (ACSF) contained 0.5 μ M TTX and 20 μ M CNQX. The seal tests were performed through the application of a –5 mV step about every 5 min to monitor the changes in access resistance. Data were collected only if the whole-cell access resistance was consistent throughout the recording (changes < 15%). All experiments were performed at 23–25 °C.

Data analysis. Values are expressed as mean \pm s.e.m. One-way ANOVA or a two-tailed Student's t-test was used for statistical analysis and P values less than 0.05 were considered to be statistically significant. Peak current amplitude and 10–90% rises time of recombinant GABA_AR-mediated response was measured by Clmapfit 10. Maximum currents (I_{\max}) were determined as the amplitude of peak currents induced by saturated concentration or indicated concentration of agonists. Dose-response curves were created by fitting data to the Hill equation: $I = I_{\max} / [1 + (EC_{50} / [A])^{n_H}]$, where I is the current, [A] is a given concentration of agonist and n_H is the Hill coefficient (GraphPad Prism 6, CA, USA). The amplitude, frequency, and rise time of mIPSCs were measured by MiniAnalysis. The amplitude of tonic currents was revealed by measuring the change in the holding current evoked by applying the GABA_AR antagonist bicuculline. The baseline current of 10 s was selected for each treatment and was analyzed by generating an all-points histogram and fitting a Gaussian distribution to the positive side of the histogram by Clampfit 10. The means of the fitted Gaussian were used to determine the holding current before and after drug application³⁹.

References

- Ross, J. A. & Kasum, C. M. Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annual review of nutrition* **22**, 19–34, doi: 10.1146/annurev.nutr.22.111401.144957 (2002).
- Miean, K. H. & Mohamed, S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. *Journal of agricultural and food chemistry* **49**, 3106–3112 (2001).
- Lopez-Lazaro, M. Distribution and biological activities of the flavonoid luteolin. *Mini reviews in medicinal chemistry* **9**, 31–59 (2009).
- Lin, Y., Shi, R., Wang, X. & Shen, H. M. Luteolin, a flavonoid with potential for cancer prevention and therapy. *Current cancer drug targets* **8**, 634–646 (2008).
- Coleta, M., Campos, M. G., Cotrim, M. D., Lima, T. C. & Cunha, A. P. Assessment of luteolin (3',4',5,7-tetrahydroxyflavone) neuropharmacological activity. *Behavioural brain research* **189**, 75–82, doi: 10.1016/j.bbr.2007.12.010 (2008).
- de la Pena, J. B. *et al.* Luteolin mediates the antidepressant-like effects of *Cirsium japonicum* in mice, possibly through modulation of the GABA_A receptor. *Archives of pharmacological research* **37**, 263–269, doi: 10.1007/s12272-013-0229-9 (2014).
- Hanrahan, J. R., Chebib, M. & Johnston, G. A. Flavonoid modulation of GABA(A) receptors. *British journal of pharmacology* **163**, 234–245, doi: 10.1111/j.1476-5381.2011.01228.x (2011).
- Hara, K. *et al.* Effects of intrathecal and intracerebroventricular administration of luteolin in a rat neuropathic pain model. *Pharmacology, biochemistry, and behavior* **125**, 78–84, doi: 10.1016/j.pbb.2014.08.011 (2014).
- Johnston, G. A. Flavonoid nutraceuticals and ionotropic receptors for the inhibitory neurotransmitter GABA. *Neurochemistry international* **89**, 120–125, doi: 10.1016/j.neuint.2015.07.013 (2015).

10. Yoo, D. Y. *et al.* Effects of luteolin on spatial memory, cell proliferation, and neuroblast differentiation in the hippocampal dentate gyrus in a scopolamine-induced amnesia model. *Neurological research* **35**, 813–820, doi: 10.1179/1743132813Y.0000000217 (2013).
11. Simon, J., Wakimoto, H., Fujita, N., Lalande, M. & Barnard, E. A. Analysis of the set of GABA(A) receptor genes in the human genome. *The Journal of biological chemistry* **279**, 41422–41435, doi: 10.1074/jbc.M401354200 (2004).
12. Olsen, R. W. & Sieghart, W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. *Pharmacological reviews* **60**, 243–260, doi: 10.1124/pr.108.00505 (2008).
13. Xiang, Y. Y. *et al.* A GABAergic system in airway epithelium is essential for mucus overproduction in asthma. *Nature medicine* **13**, 862–867, doi: 10.1038/nm1604 (2007).
14. Purwana, I. *et al.* GABA promotes human beta-cell proliferation and modulates glucose homeostasis. *Diabetes* **63**, 4197–4205, doi: 10.2337/db14-0153 (2014).
15. Soltani, N. *et al.* GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. *Proceedings of the National Academy of Sciences of the United States of America* **108**, 11692–11697, doi: 10.1073/pnas.1102715108 (2011).
16. Xu, E. *et al.* Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system. *Cell metabolism* **3**, 47–58, doi: 10.1016/j.cmet.2005.11.015 (2006).
17. Gardner, L. B. *et al.* Effect of specific activation of gamma-aminobutyric acid receptor *in vivo* on oxidative stress-induced damage after extended hepatectomy. *Hepatology research* **42**, 1131–1140, doi: 10.1111/j.1872-034X.2012.01030.x (2012).
18. Barnard, E. A. *et al.* International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function. *Pharmacological reviews* **50**, 291–313 (1998).
19. Farrant, M. & Nusser, Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. *Nature reviews. Neuroscience* **6**, 215–229, doi: 10.1038/nrn1625 (2005).
20. Collinson, N. *et al.* Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. *The Journal of neuroscience* **22**, 5572–5580, doi: 20026436 (2002).
21. Dawson, G. R. *et al.* An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. *The Journal of pharmacology and experimental therapeutics* **316**, 1335–1345, doi: 10.1124/jpet.105.092320 (2006).
22. Shaikh, M. F., Tan, K. N. & Borges, K. Anticonvulsant screening of luteolin in four mouse seizure models. *Neuroscience letters* **550**, 195–199, doi: 10.1016/j.neulet.2013.06.065 (2013).
23. Taliou, A., Zintzaras, E., Lykouras, L. & Francis, K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. *Clinical therapeutics* **35**, 592–602, doi: 10.1016/j.clinthera.2013.04.006 (2013).
24. Cao, J., Zhang, Y., Chen, W. & Zhao, X. The relationship between fasting plasma concentrations of selected flavonoids and their ordinary dietary intake. *The British journal of nutrition* **103**, 249–255, doi: 10.1017/S000711450999170X (2010).
25. Mortensen, M. & Smart, T. G. Extrasynaptic alphabeta subunit GABAA receptors on rat hippocampal pyramidal neurons. *The Journal of physiology* **577**, 841–856, doi: 10.1113/jphysiol.2006.117952 (2006).
26. Goutman, J. D., Waxemberg, M. D., Donate-Oliver, F., Pomata, P. E. & Calvo, D. J. Flavonoid modulation of ionic currents mediated by GABA(A) and GABA(C) receptors. *European journal of pharmacology* **461**, 79–87 (2003).
27. Goutman, J. D. & Calvo, D. J. Studies on the mechanisms of action of picrotoxin, quercetin and pregnanolone at the GABA rho 1 receptor. *British journal of pharmacology* **141**, 717–727, doi: 10.1038/sj.bjp.0705657 (2004).
28. Mozrzymas, J. W. Dynamism of GABA(A) receptor activation shapes the “personality” of inhibitory synapses. *Neuropharmacology* **47**, 945–960, doi: 10.1016/j.neuropharm.2004.07.003 (2004).
29. Glykys, J. & Mody, I. The main source of ambient GABA responsible for tonic inhibition in the mouse hippocampus. *The Journal of physiology* **582**, 1163–1178, doi: 10.1113/jphysiol.2007.134460 (2007).
30. Jones, M. V. & Westbrook, G. L. Desensitized states prolong GABAA channel responses to brief agonist pulses. *Neuron* **15**, 181–191 (1995).
31. Munakata, M., Jin, Y. H., Akaike, N. & Nielsen, M. Temperature-dependent effect of zolpidem on the GABAA receptor-mediated response at recombinant human GABAA receptor subtypes. *Brain research* **807**, 199–202 (1998).
32. Ramesova, S. *et al.* On the stability of the bioactive flavonoids quercetin and luteolin under oxygen-free conditions. *Analytical and bioanalytical chemistry* **402**, 975–982, doi: 10.1007/s00216-011-5504-3 (2012).
33. Zhang, C. *et al.* Neurexins physically and functionally interact with GABA(A) receptors. *Neuron* **66**, 403–416, doi: 10.1016/j.neuron.2010.04.008 (2010).
34. Dekermendjian, K. *et al.* Structure-activity relationships and molecular modeling analysis of flavonoids binding to the benzodiazepine site of the rat brain GABA(A) receptor complex. *Journal of medicinal chemistry* **42**, 4343–4350 (1999).
35. Paladini, A. C. *et al.* Flavonoids and the central nervous system: from forgotten factors to potent anxiolytic compounds. *The Journal of pharmacy and pharmacology* **51**, 519–526 (1999).
36. Kavvadias, D. *et al.* The flavone hispidulin, a benzodiazepine receptor ligand with positive allosteric properties, traverses the blood-brain barrier and exhibits anticonvulsive effects. *British journal of pharmacology* **142**, 811–820, doi: 10.1038/sj.bjp.0705828 (2004).
37. Viola, H. *et al.* Apigenin, a component of *Matricaria recutita* flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. *Planta medica* **61**, 213–216, doi: 10.1055/s-2006-958058 (1995).
38. Ramerstorfer, J. *et al.* The GABAA receptor alpha+beta- interface: a novel target for subtype selective drugs. *The Journal of neuroscience* **31**, 870–877, doi: 10.1523/JNEUROSCI.5012-10.2011 (2011).
39. Bright, D. P. & Smart, T. G. Methods for recording and measuring tonic GABAA receptor-mediated inhibition. *Frontiers in neural circuits* **7**, 193, doi: 10.3389/fncir.2013.00193 (2013).

Acknowledgements

This study was supported by grants to NZ and DCW from the Taiwan National Science Council (NSC 102-2320-B-039-038-MY3), the Ministry of Science and Technology (MOST 104-2320-B-039-045-MY3 and MOST 104-2320-B-039-048-MY3), China Medical University (CMU104-S-14-05), and the Ministry of Health and Welfare: Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Contributions

M.-L.S. and C.-H.W. performed the HEK cell experiments and analyzed the data. R.Y.-T.C. performed brain slice experiments, analyzed the data, and edited the manuscript. M.-L.S., N.Z., S.-T.K. and D.C.W. conceived the study. N.Z., S.-T.K. and D.C.W. supervised the experiments and wrote the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Shen, M.-L. *et al.* Luteolin inhibits GABA_A receptors in HEK cells and brain slices. *Sci. Rep.* **6**, 27695; doi: 10.1038/srep27695 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>